RSLS - ReShape Lifesciences Inc. Summary, Stock Quote and News

0.6423 -0.068 (-9.54%)

Data as of Dec 10, 2018

Prev. Close 0.71
Price Open 0.68
Volume 300,048
Day's Range 0.62 - 0.69
52 Wk Range 0.6954 - 3756.805929
50 Day Moving Avg. 0.53
PE Ratio 0
Shares Outstanding 3.16M
Market Cap 2.03M

Trade RSLS stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
8/03/18	Ladenburg Thalmann	Downgrades	BuyNeutral	0.0

Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018 Benzinga NewsdeskMon, 10 Dec 2018 11:01:58 -0500
The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering Shanthi RexalineThu, 06 Dec 2018 07:56:09 -0500
CVI Investments Reports 9.9% Passive Stake in Reshape Lifesciences Charles GrossThu, 06 Dec 2018 06:13:48 -0500
ReShape Lifesciences Expands International Business in the Middle East Charles GrossThu, 06 Dec 2018 06:12:46 -0500
Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018 Benzinga NewsdeskThu, 29 Nov 2018 10:59:22 -0500
The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Shanthi RexalineThu, 29 Nov 2018 08:09:42 -0500
Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018 Benzinga NewsdeskWed, 28 Nov 2018 11:54:28 -0500
The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings Shanthi RexalineWed, 28 Nov 2018 07:46:36 -0500
Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018 Benzinga NewsdeskTue, 27 Nov 2018 11:26:01 -0500
The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Shanthi RexalineTue, 27 Nov 2018 07:32:26 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

ReShape Lifesciences Expands International Business in the Middle East ACCESSWIRE4 days ago
ReShape Lifesciences Announces Live Surgery Course for ReShape Vest ACCESSWIREDec 03, 2018
ReShape Lifesciences Provides Financing and Corporate Update ACCESSWIRENov 28, 2018
ReShape Lifesciences Announces $10 Million Registered Direct Offering ACCESSWIRENov 26, 2018
ReShape Lifesciences Presents New Data on Proprietary Technology for Type 2 Diabetes ACCESSWIRENov 26, 2018
ReShape Lifesciences Announces Third Quarter 2018 Financial Results ACCESSWIRENov 14, 2018
ReShape Lifesciences Completes Investigator Meeting for ReShape Vest Clinical Trial in the European Union ACCESSWIRENov 12, 2018
ReShape Lifesciences Announces National VA Contract for ReShape Balloon ACCESSWIRENov 08, 2018
ReShape Lifesciences Announces 1-for-140 Reverse Stock Split ACCESSWIRENov 07, 2018
ReShape Lifesciences to Host Third Quarter 2018 Conference Call on November 14, 2018 ACCESSWIREOct 31, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Healthcare & Tech dominate midday movers Seeking AlphaNov 27, 2018
Arsanis and CohBar among Healthcare gainers; G1 Therapeutics and ReShape Lifesciences among the losers Seeking AlphaNov 27, 2018
ReShape shares halted pending news; shares up 7% Seeking AlphaNov 26, 2018
ReShape up 93% premarket Seeking AlphaNov 26, 2018
NVAX, RSLS among premarket gainers Seeking AlphaNov 26, 2018
Medical equipment leads Healthcare gainers; while biotechnology among the losers Seeking AlphaNov 21, 2018
Bioblast Pharma and Heat Biologics among Healthcare sector gainers; LivaNova and MiMedx among the losers Seeking AlphaNov 20, 2018
Imprimis Pharmaceuticals leads healthcare gainers; ReShape Lifesciences and Acadia Healthcare among losers Seeking AlphaNov 16, 2018
uniQure leads healthcare gainers; ReShape Lifesciences and Aptevo Therapeutics among losers Seeking AlphaNov 15, 2018
ReShape Lifesciences Inc. (RSLS) CEO Dan Gladney on Q3 2018 Results - Earnings Call Transcript Seeking AlphaNov 14, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2018	EST	Actual	Surprise
EPS:	Expected 2018-11-14
Rev:	Expected 2018-11-14

Q4 2018	EST	Actual	Surprise
EPS:	Expected 2019-04-01
Rev:	Expected 2019-04-01

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

ReShape Lifesciences Inc. RSLS:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

ReShape Lifesciences Inc. RSLS:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners